FOLH1 and prostate carcinoma: 177Lu-scFvD2B is currently under preclinical investigation because it has shown increased prostate cancer cell uptake, internalization and tumor radiation dose as compared to the Glu-ureido-based PSMA inhibitor peptides labeled with 177Lu [31,33].